NCT04397510View on ClinicalTrials.gov

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

PHASE4TerminatedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Covid-19ARDS, HumanAcute Lung Injury

Interventions

DRUG

Heparin

Nebulized Heparin

DRUG

0.9% Sodium-chloride

Nebulized 0.9% Sodium Chloride

Trial Locations (1)

21701

Frederick Health Hospital, Frederick

Sponsors

Lead Sponsor

Frederick Health

All Listed Sponsors

lead

Frederick Health

OTHER